



**Ontario  
Health**

## Memo

**Date:**

March 2, 2022

---

**To:** Primary care providers

**From:** Anna Greenberg, Chief Regional Officer, Toronto and East  
Susan deRyk, Chief Regional Officer, Central and West  
Brian Ktytor, Chief Regional Officer, North

**CC:** Mark Walton, Senior Vice President, COVID-19 Pandemic Response  
Dr. Sacha Bhatia, Population Health and Value Based Health Systems Executive

**Re:** Update on access to outpatient therapies for COVID-19

---

On January 31, 2022, Ontario Health shared a communication outlining how primary care providers can refer eligible patients to receive sotrovimab and Paxlovid on an outpatient basis. We are now writing to inform you of two updates regarding access to outpatient therapies for COVID-19:

**1) Eligibility criteria for sotrovimab and Paxlovid have been updated.**

The Ontario COVID-19 Science Advisory Table issued revised guidelines, [Therapeutic Management of Adult Patients with COVID-19](#), on February 23, 2022. These revised guidelines redefine which patients are eligible for treatment with sotrovimab and Paxlovid, with consideration to number of vaccine doses, age, and risk factors. In addition to revised eligibility criteria, the revised guidelines now recommend either sotrovimab, Paxlovid, or remdesivir as equally appropriate therapies for eligible mildly ill patients, whereas the previous guidelines recommended that sotrovimab be considered first (note that remdesivir is not typically provided on an outpatient basis due to challenges related to administration). Please review the full guidelines for details.

**2) The list of sites distributing Paxlovid is expanding.**

Ontario Health and the Ministry of Health are expanding the number of sites distributing Paxlovid in Ontario to facilitate access. The most current list of sites distributing Paxlovid, including contact information for referring clinicians, is available [here](#). This document will be updated with additional sites as information becomes available; the link will remain the same.

We have attached updated guidance that incorporates the changes outlined above, and a revised referral form for sotrovimab is also available [here](#). Questions may be directed to the Ontario Health regional contacts listed below.

Thank you for your attention to this information and for your ongoing support in ensuring your patients have access to outpatient therapies for COVID-19.

### Ontario Health regional contacts

Central	Amy Khan ( <a href="mailto:Amy.Khan@ontariohealth.ca">Amy.Khan@ontariohealth.ca</a> ) Liane Fernandes ( <a href="mailto:Liane.Fernandes@ontariohealth.ca">Liane.Fernandes@ontariohealth.ca</a> )
East	Farrah Hirji ( <a href="mailto:Farrah.Hirji@ontariohealth.ca">Farrah.Hirji@ontariohealth.ca</a> ) Leah Bartlett ( <a href="mailto:Leah.Bartlett@ontariohealth.ca">Leah.Bartlett@ontariohealth.ca</a> )
Toronto	Rose Cook ( <a href="mailto:Rose.Cook@ontariohealth.ca">Rose.Cook@ontariohealth.ca</a> )
West	Jennifer Mills Beaton ( <a href="mailto:Jennifer.MillsBeaton@ontariohealth.ca">Jennifer.MillsBeaton@ontariohealth.ca</a> ) Karen Bell ( <a href="mailto:Karen.M.Bell@ontariohealth.ca">Karen.M.Bell@ontariohealth.ca</a> )
North	Cynthia Stables ( <a href="mailto:Cynthia.Stables@ontariohealth.ca">Cynthia.Stables@ontariohealth.ca</a> ) Jennifer MacKinnon ( <a href="mailto:Jennifer.MacKinnon@ontariohealth.ca">Jennifer.MacKinnon@ontariohealth.ca</a> )